Enadenotucirev (original) (raw)

Enadenotucirev is an investigational oncolytic virus that is in clinical trials for various cancers. It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as ColoAd1. Enadenotucirev has also been modified with additional genes using the tumor-specific immuno-gene therapy (T-SIGn) platform to develop novel cancer gene therapy agents. The T-SIGn vectors at clinical study stage are: In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) designated enadenotucirev as an orphan medicinal product for the treatment of ovarian cancer.